[go: up one dir, main page]

BR0006088A - Derivados de proteìna c - Google Patents

Derivados de proteìna c

Info

Publication number
BR0006088A
BR0006088A BR0006088-7A BR0006088A BR0006088A BR 0006088 A BR0006088 A BR 0006088A BR 0006088 A BR0006088 A BR 0006088A BR 0006088 A BR0006088 A BR 0006088A
Authority
BR
Brazil
Prior art keywords
protein
derivatives
polypeptides
human
protein derivatives
Prior art date
Application number
BR0006088-7A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0006088A publication Critical patent/BR0006088A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE PROTEìNA C"<D>. São descritos novos derivados de proteína C. Estes polipeptídeos mantêm a atividade biológica da proteína C humana selecionado com semividas substancialmente mais longas em sangue humano. Estes polipeptídeos irão requerer menos administração freq³ente e/ou menor dosagem do que a proteína C humana do tipo selvagem no tratamento de desordens oclusivas vasculares, estados hipercoaguláveis, desordens trombóticas e estados de doença que predispõem a trombose.
BR0006088-7A 1999-04-30 2000-04-13 Derivados de proteìna c BR0006088A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30
PCT/US2000/008722 WO2000066754A1 (en) 1999-04-30 2000-04-13 Protein c derivatives

Publications (1)

Publication Number Publication Date
BR0006088A true BR0006088A (pt) 2001-03-20

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006088-7A BR0006088A (pt) 1999-04-30 2000-04-13 Derivados de proteìna c

Country Status (11)

Country Link
EP (1) EP1090130A1 (pt)
JP (1) JP2002542832A (pt)
KR (1) KR20010053345A (pt)
AR (1) AR029627A1 (pt)
AU (1) AU4188500A (pt)
BR (1) BR0006088A (pt)
CA (1) CA2338799A1 (pt)
HU (1) HUP0102444A3 (pt)
IL (1) IL140326A0 (pt)
PE (1) PE20010066A1 (pt)
WO (1) WO2000066754A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235915T1 (de) * 1998-11-20 2003-04-15 Lilly Co Eli Behandlung von hämorrhagischem virusfieber mit protein c
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
WO2002028416A1 (en) * 2000-09-30 2002-04-11 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインcまたは活性化プロテインc様分子
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインc配列
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c

Also Published As

Publication number Publication date
HUP0102444A3 (en) 2003-09-29
PE20010066A1 (es) 2001-02-02
JP2002542832A (ja) 2002-12-17
AU4188500A (en) 2000-11-17
CA2338799A1 (en) 2000-11-09
IL140326A0 (en) 2002-02-10
KR20010053345A (ko) 2001-06-25
HUP0102444A2 (hu) 2001-10-28
EP1090130A1 (en) 2001-04-11
WO2000066754A1 (en) 2000-11-09
AR029627A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
BR9611210A (pt) Composições e processos para tratamento de condições ósseas deficitárias
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
BR0207006A (pt) Composição farmacêutica, kit, uso de uma preparação de um fator vii ou polipeptìdeo relacionado ao fator vii em combinação com uma preparação de um fator ix ou polipeptìdeo relacionado ao fator ix, uso de uma composição, método para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia de um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em um paciente, e para intensificar a formação de coágulo de fibrina em um paciente
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
NZ210275A (en) Modified hirudin and its antithrombin properties
BR0006088A (pt) Derivados de proteìna c
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
IS6072A (is) Æðasamloðunar sameindir og mótun á starfsemi þeirra
KR950703004A (ko) 콜라겐-자극 혈소판 응집의 억제(inhibitor of collagen-stimulated platelet aggregation)
ATE211487T1 (de) Dermatansulfatezusammensetzung als antithromotisches mittel
SE0102147D0 (sv) New methods
DE3579847D1 (de) Medikamente welche die freifliessenden eigenschaften von blut verbessern und die verwendung in therapeutika.
BR0001794A (pt) Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
ATE286122T1 (de) Protein c derivate
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
BR9708005A (pt) C3 convertase resistente à regulação para baixo
BR0008703A (pt) Utilização da tianeptina para a obtenção de medicamentos destinados ao tratamento das patologias da neurodegenerescência
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
BR0014167A (pt) Proteìna iren, sua preparação e aplicação
DE69836278D1 (de) Allele formen von menschlichem stat3
BR9916858A (pt) ((aminoiminometil)amino)alcanocarboxamidas e asaplicações das mesmas em terapia

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]